Non-Syndromic X-Linked Mental Retardation Mutation Analysis

ARX, DLG3, FACL4, FTSJ1, JARID1C, PQBP1, TM4SF2, and ZNF41 genes, Full Mutation Analysis

X-linked mental retardation (XLMR) has a prevalence of 2.6 cases per 1,000 in the general population, accounting for over 10% of all cases of mental retardation1. It is estimated that 2/3 of X-linked mental retardation is non-syndromic (mental retardation without other distinguishing features). Recently, multiple genes have been indicated in non-syndromic XLMR. We have selected eight genes with strong evidence and high mutation rates to form a non-syndromic XLMR test. This test includes ARX (aristaless related homeobox)2-5, DLG3 (discs, large homolog 3)6, FACL4 (fatty acid CoA ligase 4)7, FTSJ1 (FtsJ homolog 1)8, JARID1C (Jumonji/ARID domain-containing protein 1C)9, PQBP1 (polyglutamine binding protein 1)10, TM4SF2 (transmembrane 4 superfamily member 2)11 and ZNF41(Zinc finger protein 41)12. Based on recent literature, the estimated detection rate of this XLMR test is 20-25% of non-syndromic XLMR patients.

To open a printable assay summary in a new window, click the link below.

Non-Syndromic X-Linked Mental Retardation Mutation Analysis Assay Summary 
(in portable document format (pdf) which requires Adobe® Acrobat® Reader™ to view or print; download latest version free)

Please submit the Test Request Form (TRF)  and the Neuropsychiatric Patient Information Form when ordering this test.

References
1. Stevenson RE, Schwartz CE. Cytogenet Genome Res. 2002;99(1-4):265-75.
2. Stromme P, et al. Nat Genet. 2002 Apr;30(4):441-5.
3. Uyanik G, et al. Neurology. 2003 Jul 22;61(2):232-5.
4. Hirose S, Mitsudome A. Brain Dev. 2003 Apr;25(3):161-5.
5. Stromme P, et al. Brain Dev. 2002 Aug;24(5):266-8.
6. Tarpey P., et al. Am J Hum Genet. 2004 Aug;75(2):318-24.
7. Covault J, et al. Am J Med Genet B Neuropsychiatr Genet. 2004 May 15;127(1):42-7.
8. Freude K, et al. Am J Hum Genet. 2004 Aug;75(2):305-9.
9. Jensen LR, et al. Am J Hum Genet. 2005 Feb;76(2):227-36.
10. Kalscheuer VM, et al. Nat Genet. 2003 Dec;35(4):313-5.
11. Zemni R, et al. Nat Genet. 2000 Feb;24(2):167-70.
12. Shoichet SA, et al. Am J Hum Genet. 2003 Dec;73(6):1341-54.

Back to the List of Services

Neuropsychiatric Diseases

NCI CCC LogoCity of Hope is one of 40 Comprehensive Cancer Centers, the highest designation bestowed by the National Cancer Institute and a recognition of excellence in cancer treatment, research, prevention and education.
City of Hope strongly supports and values the uniqueness of all individuals and promotes a work environment where diversity is embraced.
NCI CCC LogoThe National Comprehensive Cancer Network®
(NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HON code of the Healthcare on the Net Foundation.